title: Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha.
abstract: In this report, we found that an anti-CD44 mAb, S5, augmented conjugated formation between the effector cells (canine PBMC) and an NK-sensitive target cell line [canine thyroid adenoma carcinoma cell line (CTAC)], as determined by two different methods: conjugate enumeration using fluorescence microscopy and two-color flow cytometric analysis. However, no increase in conjugate formation was seen when an NK-resistant target was used. This enhancement of initial conjugate formation could not be blocked using an antibody to CD18 (60.3), indicating that S5 possibly acted through another adhesive molecule(s). But the NK killing activity can be partially blocked by 60.3, indicating that this molecule may be important for later adhesive events. We also found that S5 stimulated the release of a heat labile cytotoxic factor from canine PBMC. This factor was found to lyse only TNF alpha-sensitive targets (CTAC and L929 cell lines) and caused apoptosis in the target cells. Its bioactivity was neutralized by polyclonal antibody to TNF alpha. All of these observations were consistent with the fact that the factor was TNF alpha. Our data suggested that the two mechanisms responsible for the enhancement in canine NK activity by an mAb to CD44 were an increase in conjugate formation and the release of TNF alpha.
authors.affiliation: Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: P H
authors.initials: PH
authors.lastname: Tan
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: E B
authors.initials: EB
authors.lastname: Santos
authors.forename: B M
authors.initials: BM
authors.lastname: Sandmaier
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D018821:CD18 Antigens / Q000502:physiology; D002352:Carrier Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004285:Dogs; D006801:Humans; D018960:Hyaluronan Receptors; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000276:immunology*; D016201:Receptors, Lymphocyte Homing / Q000276:immunology*; D013964:Thyroid Neoplasms / Q000276:immunology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D002352:Carrier Proteins; D018960:Hyaluronan Receptors; D011956:Receptors, Cell Surface; D016201:Receptors, Lymphocyte Homing; D014409:Tumor Necrosis Factor-alpha